TEL AVIV, Israel, July 30, 2020 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a
Phase 3 clinical trial for the treatment of nonalcoholic
steatohepatitis (NASH) and fibrosis announced today that it
will host a conference call and webcast on Thursday, August 6, 2020, to provide an update on
current developments with respect to its clinical programs for
Aramchol™ and to discuss financial results for the three and six
months ended June 30, 2020.
Conference Call & Webcast:
Thursday August 6, 2020,
8:30 AM ET
Toll Free: 1-800-954-0643
Toll/International: 1-212-231-2904
Israel Toll Free: 1-809-457-756
Conference ID: 21966797
Webcast: http://public.viavid.com/index.php?id=140960
Replay Dial-In Numbers
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 21966797
Replay Start: Thursday August 6,
2020, 11:30 AM ET
Replay Expiry: Thursday August 20,
2020, 11:59 PM ET
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol's ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol on fibrosis is mediated by downregulation of steatosis and
directly on human collagen producing cells. Aramchol has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development
biopharmaceutical company for liver, metabolic and inflammatory
diseases. Our lead compound, Aramchol™, a backbone drug candidate
for the treatment of NASH and fibrosis is currently in a Phase 3
registrational study.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-second-quarter-2020-financial-results-and-provide-business-update-on-thursday-august-6-301102960.html
SOURCE Galmed Pharmaceuticals Ltd.